Payment overview · 2025
General Payments
$664.82
34 reported records · 9 companies
Healthcare provider profile · identity verified
David C Walker, DO
Allopathic & Osteopathic Physicians|Internal Medicine · SHERIDAN, WY · NPI 1639142508
Verified facts
What the public records show
CMS Open Payments records show David C Walker, DO received $664.82 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.45 | 29.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.97 | 21.8% | 10 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $83.05 | 12.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.76 | 11.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.82 | 10.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.62 | 4.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.15 | 3.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $23.70 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.30 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.82 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $144.97 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $144.97 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.14 | 6 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $83.05 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.82 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.57 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 701 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 103 |
| Losartan Potassium | Losartan Potassium | 321 | 95 |
| Furosemide | Furosemide | 313 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 308 | 83 |
| Eliquis | Apixaban | 288 | 59 |
| Potassium Chloride | Potassium Chloride | 256 | 67 |
| Omeprazole | Omeprazole | 253 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 23 |
| Gabapentin | Gabapentin | 207 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 52 |
| Metformin Hcl | Metformin Hcl | 201 | 59 |
| Lisinopril | Lisinopril | 189 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 49 |
| Trazodone Hcl | Trazodone Hcl | 172 | 50 |
| Sertraline Hcl | Sertraline Hcl | 161 | 38 |
| Montelukast Sodium | Montelukast Sodium | 151 | 43 |
| Spironolactone | Spironolactone | 129 | 32 |
| Allopurinol | Allopurinol | 127 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 48 |
| Simvastatin | Simvastatin | 126 | 38 |
| Pregabalin | Pregabalin | 122 | 31 |
| Finasteride | Finasteride | 121 | 38 |
| Ozempic | Semaglutide | 100 | 15 |
| Celecoxib | Celecoxib | 98 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 30 |
| Donepezil Hcl | Donepezil Hcl | 95 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 33 |
| Buspirone Hcl | Buspirone Hcl | 91 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 18 |
| Famotidine | Famotidine | 75 | 19 |
| Carvedilol | Carvedilol | 74 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 19 |
| Atenolol | Atenolol | 70 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 19 |
| Tramadol Hcl | Tramadol Hcl | 69 | 19 |
| Lorazepam | Lorazepam | 68 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 63 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 18 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Farxiga | Dapagliflozin Propanediol | 60 | 14 |
| Azithromycin | Azithromycin | 58 | 45 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Cephalexin | Cephalexin | 43 | 23 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Estradiol | Estradiol | 41 | 15 |
| Methylprednisolone | Methylprednisolone | 41 | 35 |
| Prednisone | Prednisone | 41 | 12 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 36 | 36 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 36 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 14 |
| Valsartan | Valsartan | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | 11 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lacosamide | Lacosamide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.82 · 34 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, CAPLYTA, EVENITY, FARXIGA, Flector, Licart, MOUNJARO, PROLIA, TRELEGY ELLIPTA, Tirosint, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error